Daix (France), Long Island City (New York, United States), May 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, announces the voting results of its Combined General Meeting.
The Combined General Meeting was held on Thursday May 19, 2022 at 2 p.m. at the Hôtel Oceania Le Jura – 14, avenue Foch – 21000 Dijon, France, under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and co-founder of ‘Inventive.